Tetravalent AΒ1-15 vaccine reduces TCR-positive cell infiltration and up-regulates p75 in Tg2576 brains compared to AΒ42 vaccine

Journal of Neuroimmunology

Volumn 219, Issue 1-2, 2010, Pages 8-16

  Li, Hui ^a,b   Zou, Juntao ^a   Yao, Zhibin ^a   Yu, Jing ^a   Wang, Huaqiao ^a   Xu, Jie ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

A 42 vaccine; Alzheimer's disease; P75; T cells; Tetravalent A 1 15 vaccine

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-15] VACCINE; AMYLOID BETA PROTEIN[1-42] VACCINE; BETA ACTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CD11B ANTIGEN; CD4 ANTIGEN; CD8ALPHA ANTIGEN; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; PROTEIN P75; PROTEIN TYROSINE KINASE A; SMAD4 PROTEIN; SMAD7 PROTEIN; SOMATOMEDIN; STAT1 PROTEIN; STAT6 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 15); AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-15); AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; GROWTH FACTOR RECEPTOR; LEUKOCYTE ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; NERVE GROWTH FACTOR RECEPTOR; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CHOROID PLEXUS; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SUBSTANTIA NIGRA; UPREGULATION; WESTERN BLOTTING; ACTIVE IMMUNIZATION; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; C57BL MOUSE; CYTOLOGY; DISEASE MODEL; GENETICS; IMMUNOLOGY; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; T LYMPHOCYTE; THYMUS; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, CD; BRAIN; DISEASE MODELS, ANIMAL; IMMUNOTHERAPY, ACTIVE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; RECEPTOR, NERVE GROWTH FACTOR; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, GROWTH FACTOR; T-LYMPHOCYTES; THYMUS GLAND; UP-REGULATION;

EID: 77249166501     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2009.11.007     Document Type: Article

References (50)

1. Agadjanyan M.G., Ghochikyan A., Petrushina I., Vasilevko V., Movsesyan N., Mkrtichyan M., Saing T., Cribbs D.H. Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J. Immunol. 2005, 3:1580-1586.
2. Britschgi M., Wyss-coray T. Immune cells may fend off Alzheimer disease. Nat. Med. 2007, 4:408-409.
3. Buckwalter M.S., Coleman B.S., Buttini M., Barbour R., Schenk D., Games D., Seubert P., Wyss-Coray T. Increased T cell recruitment to the CNS after amyloid1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta1. J. Neurosci. 2006, 44:11437-11441.
4. Butovsky O., Koronyo-Hamaoui M., Kunis G., Ophir E., Landa G., Cohen H., Schwartz M. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. PNAS 2006, 103:11784-11789.
5. Cao C., Arendash G.W., Dickson A., Mamcarz M.B., Lin X., Ethell D.W. Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol. Dis. 2009, 1:63-70.
6. Coulson E.J., May L.M., Sykes A.M., Hamlin A.S. The role of the p75 neurotrophin receptor in cholinergic dysfunction in Alzheimer's disease. Neuroscientist 2009, 15:317-323.
7. Crutcher K.A., Gendelman H.E., Kipnis J., Perez-Polo J.R., Perry V.H., Popovich P.G., Weaver L.C. Debate: "is increasing neuroinflammation beneficial for neural repair?". J. Neuroimmune Pharmacol. 2006, 3:195-211.
8. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease. PNAS 2001, 15:8850-8855.
9. Donna M.W., Carol A.C. Anti-Aß immunotherapy in Alzheimer's disease; relevance of transgenic mouse studies to clinical trials. J. Alzheimers Dis. 2008, 4:555-569.
10. El Khoury J., Toft M., Hickman S.E., Means T.K., Terada K., Geula C., Luster A.D. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 2007, 13:432-438.
11. Engelhardt B. Regulation of immune cell entry into the central nervous system. Results Probl. Cell Differ. 2006, 43:259-280.
12. Engelhardt B., Ransohoff R.M. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 2005, 9:485-496.
13. Esiri M.M. The interplay between inflammation and neurodegeneration in CNS disease. J. Neuroimmunol. 2007, 1-2:4-16.
14. Flügel A., Berkowicz T., Ritter T., Labeur M., Jenne D.E., Li Z., Ellwart J.W., Willem M., Lassmann H., Wekerle H. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 2001, 5:547-560.
15. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B, Forette F., Orgogozo J.M Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562. AN1792(QS-21)-201 Study Team.
16. Goedert M., Spillantini M.G. A century of Alzheimer's disease. Science 2006, 314:777-781.
17. Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D., Iadecola C., Clark H.B., Carlson G. Age-related CNS disorder and earlydeath in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995, 5:1203-1218.
18. NTR cholinergic basal forebrain septohippocampal pathway. Exp. Neurol. 2001, 170:227-243.
19. Kernie S.G., Parada L.F. The molecular basis for understanding neurotrophins and their relevance to neurologic disease. Arch. Neurol. 2000, 57:654-657.
20. Kerschensteiner M., Stadelmann C., Dechant G., Wekerle H., Hohlfeld R. Neurotrophic cross-talk between the nervous and immune systems: implications for neurological disease. Ann. Neurol. 2003, 3:292-304.
21. Kipnis J., Mizrahi T., Hauben E., Shevach I., Schwartz M. Neuroprotective autoimmunity: naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. PNAS 2002, 24:15620-15625.
22. Knowles J.K., Rajadas J., Nguyen T.V., Yang T., LeMieux M.C., Vander Griend L., Ishikawa C., Massa S.M., Wyss-Coray T., Longo F.M. The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo. J. Neurosci. 2009, 29:10627-10637.
23. Kohm A.P., Carpentier P.A., Anger H.A., Miller S.D. Cutting edge: CD4+CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 2002, 9:4712-4716.
24. Larbi A., Pawelec G., Witkowski J.M., Schipper H.M., Derhovanessian E., Goldeck D., Fulop T. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J. Alzheimers Dis. 2009, 1:91-103.
25. Laurie C., Reynolds A., Coskun O., Bowman E., Gendelman H.E., Mosley R.L. CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. J. Neuroimmunol. 2007, 1-2:60-68.
26. Lazarov O., Robinson J., Tang Y.P., Hairston I.S., Korade-Mirnics Z., Lee V.M., Hersh L.B., Sapolsky R.M., Mirnics K., Sisodia S.S. Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 2005, 120:701-713.
27. Lee V.M. Abeta immunization: moving Abeta peptide from brain to blood. PNAS 2001, 16:8931-8932.
28. Lemere C.A. Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. Prog. Brain Res. 2009, 175:83-93.
29. Li M., Shang D.S., Zhao W.D., Tian L., Li B., Fang W.G., Zhu L., Man S.M., Chen Y.H. Amyloid-beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J. Immunol. 2009, 9:5778-5788.
30. Longo F.M., Yang T., Knowles J.K., Xie Y., Moore L.A., Massa S.M. Small molecule neurotrophin receptor ligands: novel strategies for targeting Alzheimer's disease mechanisms. Curr. Alzheimer Res. 2007, 4:503-506.
31. Matrone C., Marolda R., Ciafrè S., Ciotti M.T., Mercanti D., Calissano P. Tyrosine kinase nerve growth factor receptor switches from prosurvival to proapoptotic activity via Abeta-mediated phosphorylation. PNAS 2009, 106:11358-11363.
32. Mufson E.J., Counts S.E., Perez S.E., Ginsberg S.D. Cholinergic system during the progression of Alzheimer's disease: therapeutic implications. Expert Rev. Neurother. 2008, 8:1703-1718.
33. NTR immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J. Comp. Neurol. 2002, 443:136-153.
34. Moretto N., Bolchi A., Rivetti C., Imbimbo B.P., Villetti G., Pietrini V., Polonelli L., Del Signore S., Smith K.M., Ferrante R.J., Ottonello S. Conformation-sensitive antibodies against Alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. J. Biol. Chem. 2007, 15:11436-11445.
35. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 2003, 4:448-452.
36. O'Neill J.K., Butter C., Baker D., Gschmeissner S.E., Kraal G., Butcher E.C., Turk J.L. Expression of vascular addressins and ICAM-1 by endothelial cells in the spinal cord during chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse. Immunology 1991, 72:520-525.
37. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after AbetAΒ42 immunization. Neurology 2003, 1:46-54.
38. Reynolds A.D., Banerjee R., Liu J., Gendelman H.E., Mosley R.L. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J. Leukoc. Biol. 2007, 5:1083-1094.
39. Roberson E.D., Mucke L. 100years and counting: prospects for defeating Alzheimer's disease. Science 2006, 314:781.
40. Rosenkranz D., Weyer S., Tolosa E., Gaenslen A., Berg D., Leyhe T., Gasser T., Stoltze L. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J. Neuroimmunol. 2007, 1-2:117-127.
41. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 2002, 10:824-828.
42. Seabrook T.J., Thomas K., Jiang L., Bloom J., Spooner E., Maier M., Bitan G., Lemere C.A. Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. Neurobiol. Aging 2007, 6:813-823.
43. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol. 2002, 1:3.
44. Sotthibundhu A., Sykes A.M., Fox B., Underwood C.K., Thangnipon W., Coulson E.J. Beta-amyloid(1-42) induces neuronal death through the p75 neurotrophin receptor. J. Neurosci. 2008, 28:3941-3946.
45. Sotthibundhu A, Li QX, Thangnipon W, Coulson EJ. 2008. Abeta(1-42) stimulates adult SVZ neurogenesis through the p75 neurotrophin receptor. Neurobiol Aging. in press. Available online. PMID: 18374455.
46. Villoslada P., Genain C.P. Role of nerve growth factor and other trophic factors in brain inflammation. Prog. Brain Res. 2004, 146:403-414.
47. Zhang Y., Hong Y., Bounhar Y., Blacker M., Roucou X., Tounekti O., Vereker E., Bowers W.J., Federoff H.J., Goodyer C.G., LeBlanc A. p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. J. Neurosci. 2003, 23:7385-7394.
48. Zhou J., Fonseca M.I., Kayed R., Hernandez I., Webster S.D., Yazan O., Cribbs D.H., Glabe C.G., Tenner A.J. Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J. Neuroinflammation. 2005, 2:28.
49. Ziv Y., Ron N., Butovsky O., Landa G., Sudai E., Greenberg N., Cohen H., Kipnis J., Schwartz M. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat. Neurosci. 2006, 2:268-275.
50. Zou J.T., Yao Z.B., Zhang G., Wang H.Q., Xu J., Yew D.T., Forster E.L. Vaccination of Alzheimer's model mice with adenovirus vector containing tetravalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response. J. Neurol. Sci. 2008, 1-2:87-98.